Can a domestic CAR-T trial bridge the gap for lymphoma patients awaiting Yescarta?

Coverage, in order

1. 2d ago
   Korea Biomedical Review South Korea obscure study

   Can a domestic CAR-T trial bridge the gap for lymphoma patients awaiting Yescarta?

   Access to CAR-T therapy for Korean patients with diffuse large B-cell lymphoma (DLBCL) could expand as Gilead renews its reimbursement bid for Yescarta and Curocell prepares a second-line trial of Rimqarto.Yescarta (axicabtagene ciloleucel) is back under review for second-line coverage, while Curoce

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.